Related Experiment Videos
Recombinant gamma-interferon has activity in chronic myeloid leukemia
R T Silver1, P Benn, R S Verma
1Division of Hematology/Oncology, New York Hospital-Cornell Medical Center, NY 10021.
American Journal of Clinical Oncology
|February 1, 1990
Summary
Recombinant interferon-gamma (rIFN gamma) showed clinical effectiveness in chronic myeloid leukemia patients, inducing temporary normal cells. However, the treatment did not alter the disease's fundamental nature.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Philadelphia-chromosome-positive chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Effective treatments for CML are crucial for patient outcomes.
Purpose of the Study:
- To evaluate the clinical effectiveness of recombinant interferon-gamma (rIFN gamma) in patients with Philadelphia-chromosome-positive chronic myeloid leukemia.
Main Methods:
- 18 patients with Philadelphia-positive CML received rIFN gamma treatment.
- Cytogenetic and molecular analyses were performed regularly.
- Treatment involved intravenous administration of 1.5 mg/m2, three times weekly.
Main Results:
- Hematologic responses (complete or partial) were observed in 6 out of 13 treated patients.
- Two patients achieved approximately 20% normal metaphases after 74 weeks, but reverted to 100% Philadelphia-positive cells within 30 weeks.
- No significant changes were noted in breakpoint cluster region rearrangements, marrow cellularity, or leukocyte alkaline phosphatase scores.
Conclusions:
- rIFN gamma demonstrates clinical effectiveness in a subset of CML patients.
- The treatment did not alter the underlying disease biology or achieve a cure.